- Regeneron Pharmaceuticals (REGN, Financial) partners with FUJIFILM Diosynth Biotechnologies for a $3 billion, 10-year manufacturing agreement.
- Expansion creates 1,000 high-skill jobs at Tarrytown campus as part of a $3.6 billion investment.
- Total planned infrastructure investments in New York and North Carolina exceed $7 billion, enhancing U.S. manufacturing capacity.
Regeneron Pharmaceuticals, Inc. (REGN) has announced a significant expansion of its manufacturing capabilities through a strategic partnership with FUJIFILM Diosynth Biotechnologies. This 10-year agreement is valued at over $3 billion and aims to nearly double the company's U.S. large-scale manufacturing capacity by leveraging Fujifilm's state-of-the-art facility in Holly Springs, North Carolina.
This partnership is part of Regeneron's broader strategy to enhance production capabilities due to growing demand for its biologic medicines. The immediate technology transfer plan aims to rapidly increase manufacturing capacity, with significant investments being made in both New York and North Carolina.
In addition to the Fujifilm agreement, Regeneron is investing $3.6 billion to expand its Tarrytown, New York campus. This expansion will create 1,000 full-time, high-skill jobs, strengthening the research, preclinical manufacturing, and support facilities at the site. Furthermore, Regeneron is developing new facilities in Rensselaer and has acquired over a million-square-foot property in Saratoga Springs for production support and potential additional manufacturing.
Over the past five years, Regeneron has added more than 7,000 jobs, primarily in R&D and manufacturing within the United States. The company's total planned investments in infrastructure and manufacturing for New York and North Carolina are expected to exceed $7 billion.
